Oxis Turbohaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbohaler, is a long‑acting β2‑adrenergic agonist presented as a dry‑powder inhaler for inhalation use. It provides bronchodilation for patients with reversible airway obstruction, primarily asthma and chronic obstructive pulmonary disease. GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Formoterol fumarate dihydrate is a bronchodilator that acts on the β2‑adrenergic pathway to relax airway smooth muscle. - Asthma: improves lung function and reduces symptoms such as wheeze and shortness of breath. - Chronic obstructive pulmonary disease (COPD): maintains airway patency and helps prevent exacerbations. - Exercise‑induced bronchoconstriction: provides rapid onset bronchodilation to enable physical activity. - Seasonal allergic rhinitis with lower airway involvement: assists in controlling concurrent bronchospasm.

Formoterol may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Tremor: mild shaking of the hands. - Headache: transient headache. - Throat irritation: mild discomfort in the throat after inhalation. - Cough: brief cough immediately after use. - Palpitations: sensation of rapid or irregular heartbeat. - Nasal congestion: mild nasal blockage.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Cardiac arrhythmia: irregular heart rhythm that may require medical attention. - Hypokalemia: low blood potassium levels. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Hyperglycaemia: elevated blood glucose in susceptible individuals. - Pulmonary hypertension: increased pressure in lung arteries (rare).

When using Oxis Turbohaler, patients and healthcare professionals should consider several safety measures. - Assess respiratory status: confirm diagnosis of asthma or COPD before initiating therapy. - Review contraindications: avoid use in patients with known hypersensitivity to formoterol or excipients. - Monitor cardiac function: observe for tachycardia or arrhythmias, especially in patients with heart disease. - Educate on inhaler technique: ensure proper device handling to achieve correct dosing. - Evaluate pregnancy and lactation: discuss potential risks and benefits with a prescriber. - Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Formoteric is a β‑beta‑beta  

Major  

t  t .

g .

t .

\